



Psychedelic-Assisted Therapy: A Review

Emerging treatments in mental health disorders.

ABSTRACT: Psychedelics are a class of psychoactive substances that were studied extensively between 1943 and 1970 as potential therapies for treating a host of mental health disorders, including addiction. Despite promising early results, U.S. psychedelic research was halted in the early 1970s with the enactment of the Controlled Substances Act. As the field of psychedelic-assisted therapy develops, nurses can decide the role they will play in the continuing clinical and scholarly research of these substances, which may soon be used in controlled settings to treat some of the most widespread mental health disorders. To prepare for this task, this article proposes that nurses

- become familiar with the history, relevant language, and scientific findings related to the field of psychedelic research.
- learn about existing psychedelic-assisted therapy and research resources.
- examine their thoughts, judgments, and opinions about therapeutic psychedelic use.
- consider the potential role of nursing in psychedelic-assisted therapies going forward.

Keywords: entheogens, hallucinogens, holistic nursing, palliative care, psychedelic-assisted therapy, psychedelics, psychiatric nursing

In February 1964, *AJN* published an article by Kay Parley entitled, “Supporting the Patient on LSD Day.”¹ In this work, Parley discussed nursing considerations when administering therapy with lysergic acid diethylamide (LSD), a psychedelic drug, which was under research as an adjunct to traditional psychiatric treatments for patients with alcohol use disorder. Parley described the process of “sitting” with patients over the course of a daylong LSD experience on the psychiatric unit. Since LSD can cause intense emotional experiences in people who ingest it, the duties of the nurse were to bear witness, create a safe and therapeutic environment, provide reassurance during moments of fear or anxiety, serve as a grounding presence to orient the patient to the “here and now,” and encourage the patient to explore what might emerge mentally, emotionally, or spiritually on their “journey.” In fact, Parley would narrate the experience to her patients, using the following words¹:

You are off on a trip . . . with no baggage, no destination, and no compass. That’s why I’m here. I can’t go with you, but I can be your anchor. Wherever you go, you’ll always be able to see me. I’ll be the nurse who sits beside your bed, taking notes and playing your records. You’ll never lose touch with me. Seeing me, you’ll know you are really in hospital and that you’ll be back to earth about four o’clock. I will send you signals, too, to encourage your explorations. I will remind you of places you longed to revisit and events you hoped to scan.

Parley was noting what early researchers had discovered: that the psychedelic experience led patients to “scan their life” and gain new perspectives, find meaning related to past events and relationships, explore traumatic wounds, gain insights into the cause of their illness, or experience a range of emotions that often led to self-healing and self-understanding. In much the same way that nurses



An MDMA therapy session is conducted by researchers Marcela Ot'alora, MA, LPC, and Bruce Poulter, MPH, RN. Photo courtesy of the Multidisciplinary Association for Psychedelic Studies.

create conditions conducive to self-healing of the body (by keeping a wound clean and well dressed, for example), the nurse-guided psychedelic experience often allowed patients to discover their capacity for emotional healing.

A 'renaissance' in psychedelic therapy. Fifty-seven years after publication of Parley's article, psychedelic-assisted therapy is experiencing what Sessa has called a "renaissance" across the United States and internationally.² To clinicians trained after these compounds had been added to Schedule I of the Comprehensive Drug Abuse Prevention and Control Act of 1970, more commonly known as the Controlled Substances Act, psychedelics may be more commonly considered drugs of abuse than potential therapies. While psychedelics are not yet approved by the U.S. Food and Drug Administration (FDA) for this purpose, one such substance, 3,4-methylenedioxymethamphetamine (MDMA), is currently in a phase 3 clinical trial as an adjunct to psychotherapy for posttraumatic stress disorder (PTSD),³ and psi-

locybin is currently in two phase 2 clinical trials as an adjunct to psychotherapy for major depressive disorder (MDD).^{4,5} Both substances have been granted "breakthrough therapy designation" by the FDA, meaning they may offer substantial benefits over existing treatment options.⁶

Psychedelic research centers are being established both privately and within academe,^{7,8} and psychedelic therapy training programs are certifying practitioners to meet a future projected need for psychedelic-assisted therapy.⁸ The popular press has accelerated interest in the field with stories appearing in the *New York Times*,⁹ in *Psychology Today*,¹⁰ on *60 Minutes*,¹¹ and with the publication of Michael Pollan's bestselling book, *How to Change Your Mind*.¹²

With the growing interest in psychedelic therapy within academia, research, education, and society at large, the nursing profession is faced with an important choice: to actively participate in the developing field of psychedelic therapy or to allow other disciplines to guide the conversation. As Parley's 1964

AJN article suggests, nurses have a history with psychedelic-assisted therapies,¹ and there is much nurses can learn in order to prepare for the potential rescheduling of these therapies—assigning them to a schedule with fewer regulatory restrictions, for example—particularly in the areas of psychiatry, palliative care, and addiction treatment. This article discusses the history, relevant language, and scientific findings related to psychedelic-assisted therapies; the methods of self-reflection nurses can use to clarify their thoughts, judgments, and opinions about the therapeutic use of psychedelics; and the various roles nurses might play in the future of psychedelic-assisted therapy.

HISTORICAL USES OF PSYCHEDELICS

Psychedelics, also known as hallucinogens (in both the scientific and popular literature), are a class of psychoactive substances thought to “expand consciousness.” These include such substances as MDMA, which is developed in a laboratory; LSD, which is synthesized in a laboratory from an ergot fungus; and plant and fungi derivatives, often called entheogens, which include psilocybin (the active compound in “magic” mushrooms), ayahuasca, peyote, and iboga.

The entheogens psilocybin, ayahuasca, peyote, iboga, and others have been used for millennia in some cultures as traditional, sacred medicines for physical and emotional healing and as a means of making contact with the divine.¹³ Psychedelics came to the attention of Western culture as early as the 1950s and remained a focus of several Western empirical studies in mental health from the 1950s through the 1970s.¹⁴ Despite promising early results, social and political pressures halted psychedelic research in the early 1970s.¹⁴

In 1990, MDD was the second leading cause of years lived with disability (YLD) in the United States, remaining the second leading cause of YLD in 2016.¹⁵ Given the lack of significant advancements in psychopharmacology for depression over this nearly 30-year period, some researchers have been seeking to revive the dormant research on psychedelic-assisted therapy.

THE WIDE-RANGING EFFECTS OF PSYCHEDELICS

Psychedelics are a diverse class of psychoactive substances that exert a wide range of neurochemical, neuromodulatory, and hemodynamic effects on the brain.

Classic psychedelics such as psilocybin and LSD activate the serotonergic system, specifically by way of serotonin 1A, 2A, 2C, and 7 receptors, as well as the dopaminergic system through D2 receptors.¹⁶ They interact indirectly with glutamatergic and GABAergic pathways.¹⁶ There is also evidence that psychedelics affect epigenetic expression.¹⁷

MDMA is considered an atypical psychedelic, or entactogen (for its empathy enhancing effects),¹⁸ which results from the release of serotonin, enhanced dopamine,¹⁹ prolactin,²⁰ and oxytocin²¹ in multiple brain regions. Subjective effects of psychedelics may include open- or closed-eye imagery, acute emotional experiences, and anti-amnesic effects, which permit the retrieval of previously unconscious material.¹⁶

PSYCHEDELIC USE IN PSYCHOTHERAPY

The serendipitous synthesis of LSD in 1943 by Swiss chemist Albert Hofmann²² marked the beginning of the modern Western psychedelic era. Initially, LSD was used as an adjunct to psychotherapy for the treatment of alcohol use disorder, depression, and anxiety.² These treatments were halted, however, when the diversion of LSD into the popular culture led to its prohibition in 1970. After that time, LSD and other psychedelics were considered potential drugs of abuse and were classified as Schedule I substances along with other illegal drugs such as marijuana and heroin.

In 1994, researchers began reexamining the potential use of psychedelics in psychiatry. Then, as now, the studies followed a similar model: the administration of a psychoactive substance, such as psilocybin, bookended by sessions of psychotherapy conducted before the dosing session to prepare participants and afterward to help them integrate their psychedelic experience. The psychedelic substance is typically given orally, and two therapists remain with the patient in a comfortable environment for the duration of its effects, typically 12 to 24 hours. Patients may choose to talk to the therapists during the dosing session or to focus their attention inward, using eyeshades and music as aides in the process.²³

PSILOCYBIN AS A THERAPEUTIC ADJUNCT

Psilocybin has been studied as an adjunct treatment for tobacco cessation,²⁴ alcohol dependence,²⁵ anxiety and depression related to life-limiting illness,²⁶⁻²⁸ and demoralization experienced by long-term AIDS survivors.²⁹

In a study of 29 patients with cancer-related depression and anxiety, participants experienced clinically significant reductions in measures of depression and anxiety following psilocybin-assisted therapy, with 60% to 80% of those still alive at the 4.5-year follow-up continuing to show significant improvements, which 71% to 100% attributed to the psilocybin-assisted therapy.³⁰

An open-label feasibility trial of psilocybin-assisted psychotherapy, which involved six men and six women with moderate-to-severe, uni-polar, treatment-resistant MDD, produced

antidepressant effects after one week, improvements that were sustained for most patients three months later. The adverse effects of psilocybin were transient and mild. These included anxiety during drug onset, which could be managed with reassurance from study therapists, as well as confusion, nausea, and headache.³¹ In October 2018 and November 2019, the FDA granted COMPASS Pathways and the Usona Institute, respectively, breakthrough designation to conduct phase 2 clinical trials of psilocybin as an adjunct to psychotherapy for MDD.^{4,5,32}

A subsequent study of psilocybin-assisted psychotherapy for MDD was conducted at the Johns Hopkins Center for Psychedelic and Consciousness Research and demonstrated similar antidepressant effects persisting at one and four weeks following treatment.³³

RECREATIONAL VS. CLINICAL USE OF PSILOCYBIN AND MDMA

In a survey of psilocybin use in the community, 2.6% of 1,993 respondents reported that after having consumed psilocybin mushrooms they had acted in a physically aggressive manner toward themselves or others, 2.7% reported having sought medical help, and 10.7% reported putting themselves or others at risk for physical harm.³⁴

The absence of such negative consequences in the clinical setting highlights the importance of therapeutic preparation and support for the psychedelic experience. The negative psychosocial outcomes reported with recreational use have not been observed in any therapeutic study. In a study by Griffiths and colleagues that included 56 participants, there were no serious adverse events attributed to psilocybin, only transient episodes of distress or discomfort, none of which required medical intervention.²⁶ Similarly, in a randomized, blinded, controlled crossover study investigating the efficacy of psilocybin compared with a control (niacin) in treating clinically significant anxiety or depression in 31 patients with life-threatening cancer, there were no serious adverse events, medical or psychiatric, attributed to psilocybin or niacin that required medical treatment.²⁸

Although some retrospective studies of recreational use of ecstasy (street MDMA, which is often adulterated with other substances) report cognitive decline in users, especially in the area of verbal memory,³⁵ neurocognitive decline has been neither observed in clinical settings nor reported by participants in long-term follow-up.^{36,37} These contradictory findings highlight the difference between clinical and recreational use of psychedelics, potentially related to the quality of the drugs as well as to the clinical monitoring and the therapeutic paradigm.

MDMA FOR PTSD

MDMA has been under study for many years as a psychotherapeutic adjunct for treating PTSD. The drug is thought to permit patients with PTSD to better tolerate the examination of traumatic material in therapy. Researchers conducting a long-term follow-up of an early phase 2 pilot study found that, when queried, participants indicated that the benefit of MDMA-assisted psychotherapy persisted on average 3.75 years after the pilot study had ended.^{37,38} Furthermore, a pooled analysis of six phase 2 randomized controlled trials revealed that 54.2% of subjects treated with MDMA-assisted psychotherapy for PTSD no longer met the PTSD diagnostic criteria, compared with 22.6% in the placebo group. The treatment was generally well tolerated, with anxiety, fatigue, headache, bruxism, and loss of appetite the most common adverse effects.³⁶ These findings led the FDA to grant MDMA breakthrough status, allowing the initiation of its use in a phase 3 clinical trial as an adjunct to psychotherapy for PTSD.^{3,6}

THE ROLE OF NURSING IN PSYCHEDELIC-ASSISTED THERAPY

Given the emerging data in the area of psychedelic-assisted therapy, it's impossible to know the specific roles nurses will play; however, gaining a robust understanding of psychedelic pharmacology, efficacy, and safety would enable nurses to discuss the responsible use of these therapies with patients or refer patients to appropriate clinical trials. In 2020, after conducting qualitative, semistructured interviews with an interdisciplinary, expert panel of clinicians working in the areas of oncology, psychosocial oncology, palliative care, and psychiatry, researchers created a conceptual framework for integrating psychedelic therapies into extant models of care for patients with serious illness.³⁹ Nurses were among the professionals providing feedback and expert guidance in refining the interview guide. These interviews with clinicians and the framework for integration they inspired suggest the need for continued testing of psychedelic-assisted therapies to better evaluate their benefits, risks, and underlying mechanisms of action, as well as the need to develop approaches for adapting treatments to therapeutic, institutional, and societal contexts as appropriate.

Nurses have called for increased interdisciplinary collaboration from researchers, clinical experts, and scholars in the nursing field in order to safely guide the integration of psychedelic-assisted therapies into models of care for serious illness, which will be essential going forward.⁴⁰

A recent scoping review of psychedelic-assisted therapy that included literature from the past 20 years revealed that while relevant research continues to grow, the voice of nursing is notably absent.⁴¹ While professions, such as medicine,

Table 1. Research Resources for Psychedelic-Assisted Therapy

Organization	Mission/Aim/Purpose	Website
Beckley Foundation	To fund scientific investigation into the effects of neuroscience psychoactive substances on consciousness and to achieve evidence-based changes in global drug policy	https://beckleyfoundation.org
Center for Psychedelic Therapies and Research at the California Institute of Integral Studies	To train licensed health care professionals and clergy to conduct psychedelic research and therapy	www.ciis.edu/research-centers/center-for-psychedelic-therapies-and-research
Johns Hopkins Center for Psychedelic and Consciousness Research	To perform clinical research into the effects of psychedelics on brain function and psychiatric conditions	https://hopkinspsychedelic.org
Multidisciplinary Association for Psychedelic Studies	Nonprofit research and educational organization that develops medical, legal, and cultural contexts in which people can benefit from the uses of psychedelics and marijuana	https://maps.org
Organization of Psychedelic and Entheogenic Nurses	Professional organization advocating for ethical best practices and the inclusion of nurses in psychedelic-assisted psychotherapy	www.openurses.org
Usona Institute	Nonprofit medical research organization conducting phase 3 clinical trials of psilocybin for the treatment of major depression	https://usonaclinicaltrials.org

psychopharmacology, and psychology have published findings on advancements in the area of psychedelic-assisted therapies, nursing has lagged behind in disseminating related information.⁴² The absence of nursing collaboration and nurse leaders in the field presents an opportunity to consider whether explicit or implicit biases regarding the use of psychedelics are factors in this trend.

HOW NURSES CAN PREPARE TO ENTER THIS GROWING FIELD

Nurses with an interest in psychedelic-assisted therapy should first examine any implicit or explicit biases they may have about psychedelic substances or people who use them. Keeping in mind that holistic nursing recognizes multiple ways of healing, such as symbolic language; imagery; aesthetic therapies; meditation; and spiritual practices, including indigenous traditions, which may be integrated with modern clinical paradigms, we encourage nurses to gauge their unconscious attitudes toward drug use and mental illness by taking an implicit association test (IAT). The mental illness IAT and the marijuana risk IAT are available on the Project Implicit website (see <https://implicit.harvard.edu/implicit/user/pih/pih/selectatest.html>). It would also be helpful to read

and critically appraise studies linking psychedelic-assisted psychotherapies with improving mental health and overcoming addictive behaviors, as well as reports differentiating therapeutic psychedelic use from recreational use.⁴³

Nurses hoping to become involved in this growing field can pursue the following avenues:

- Explore resources for psychedelic-assisted therapy and research (see Table 1).
- Express interest in the field to psychiatric, palliative, and holistic nursing organizations that offer further education and training on this topic.
- Participate in conferences on psychedelic-assisted therapies.
- Work in clinical trials as a therapist or researcher and add to the literature on psychedelic-assisted therapy.
- Complete training to become a psychedelic therapist in anticipation of the rescheduling of psychedelic treatments.

THE IMPORTANCE OF NURSING COMPETENCIES IN THIS AREA

The knowledge, skills, and values nurses bring to patient care are central to the therapeutic use of psychedelic-assisted psychotherapy. As Phelps

has pointed out, the competencies needed to sit with a patient as a psychedelic therapist include the skills long associated with nursing's humanistic, biopsychosocial approach to care, specifically, "empathetic abiding presence, trust enhancement, spiritual intelligence, knowledge of the physical and psychological effects of psychedelics, therapist self-awareness and ethical integrity, and proficiency in complementary techniques."⁸ These competencies align with a holistic philosophy of nursing and an integrative, whole person framework that prioritizes values such as a caring presence and spiritual healing.^{44, 45}

Nurses are skilled in holding space as patients endure challenging events in real time and for prolonged periods, whether that be during childbirth, a sudden illness, an anxiety attack, or the time surrounding death. This skill translates well to being able to sit with a patient undergoing a therapeutic psychedelic experience, allowing space for whatever arises at physical, emotional, mental, or spiritual levels. Nurses can witness patient stories and help patients find meaning in these narratives, a crucial task in integrating the therapeutic psychedelic experience. Advanced practice nurses can play a crucial role in creating guidelines for assessing patients for psychedelic-assisted therapy and in providing a firm foundation of professional ethics on which to train other nurses, an area in which the voice and experience of nurses, a consistently trusted profession, would be an asset.

The growing field of psychedelic therapy will greatly benefit from nursing participation in the interdisciplinary effort to develop safe, effective clinical approaches to psychedelic-assisted therapies. Taking the baton from predecessors like Kay Parley, nurses can help create new solutions for the issues facing patients today. Psychedelic-assisted therapies offer great potential to alleviate suffering and cultivate healing, growth, and peace amid illness, and nurses are well prepared to contribute. ▼

For 117 additional nursing continuing professional development activities related to psychosocial/psychiatric nursing, go to www.nursingcenter.com.

Andrew Penn is an associate clinical professor in the University of California, San Francisco School of Nursing. Caroline G. Dorsen is an associate professor and associate dean for advanced practice and clinical partnerships at Rutgers University School of Nursing, Newark, NJ. Stephanie Hope is founder, educator, and coach at Hope Holistic Wellness, Woodbourne, NY. William E. Rosa is a psycho-oncology postdoctoral research fellow in the Department of Psychiatry and Behavioral Sciences at Memorial Sloan Kettering Cancer Center, New York City. Andrew Penn receives salary support for his work as coinvestigator on a clinical trial of psilocybin-facilitated therapy for depression (NCT03866174). William E. Rosa is funded by the NIH/NCI Cancer Center Support Grant P30 CA008748 and the NCI award number T32 CA009461.

Contact author: Andrew Penn, andrew.penn@ucsf.edu. The authors and planners have disclosed no potential conflicts of interest, financial or otherwise. A podcast with the authors is available at www.ajnonline.com.

REFERENCES

1. Parley K. Supporting the patient on LSD day. *Am J Nurs* 1964;64(2):80-2.
2. Sessa B. *The psychedelic renaissance: reassessing the role of psychedelic drugs in 21st century psychiatry and society*. London: Muswell Hill Press; 2012.
3. Multidisciplinary Association for Psychedelic Studies. *A multi-site phase 3 study of MDMA-assisted psychotherapy for PTSD*. Bethesda, MD: National Institutes of Health, National Library of Medicine; 2021 Feb. NCT04077437. ClinicalTrials.gov; <https://clinicaltrials.gov/ct2/show/NCT04077437>.
4. COMPASS Pathways. *The safety and efficacy of psilocybin as an adjunctive therapy in participants with treatment resistant depression*. Bethesda, MD: National Institutes of Health, National Library of Medicine; 2021 Feb. NCT04739865. ClinicalTrials.gov; <https://clinicaltrials.gov/ct2/show/NCT04739865>.
5. Usona Institute. *A study of psilocybin for major depressive disorder (MDD)*. Bethesda, MD: National Institutes of Health, National Library of Medicine; 2021 Jan 7. NCT03866174. ClinicalTrials.gov; <https://clinicaltrials.gov/ct2/show/NCT03866174>.
6. Multidisciplinary Association for Psychedelic Studies. FDA grants breakthrough therapy designation for MDMA-assisted psychotherapy for PTSD, agrees on special protocol assessment for Phase 3 trials [press release]. 2017 Aug 26. <https://maps.org/news/media/6786-press-release-fda-grants-breakthrough-therapy-designation-for-mdma-assisted-psychotherapy-for-ptsd,-agrees-on-special-protocol-assessment-for-phase-3-trials>.
7. Carey B. Johns Hopkins opens new center for psychedelic research. *New York Times* 2019 Sep 4. <https://www.nytimes.com/2019/09/04/science/psychedelic-drugs-hopkins-depression.html>.
8. Phelps J. Developing guidelines and competencies for the training of psychedelic therapists. *J Humanist Psychol* 2017;57(5):450-87.
9. Holson LM. Psychedelic mushrooms are closer to medicinal use (it's not just your imagination). *New York Times* 2018 Oct 3. <https://www.nytimes.com/2018/10/03/science/magic-mushrooms-psilocybin-scheduleiv.html>.
10. Bleyer J. A radical new approach to beating addiction. *Psychol Today* 2017 May. <https://www.psychologytoday.com/us/articles/201705/radical-new-approach-beating-addiction>.
11. Cooper A. Psilocybin sessions: psychedelics could help people with addictions and anxiety. *60 Minutes* 2020 Aug 16. <https://www.cbsnews.com/news/psychedelic-drugs-isd-active-agent-in-magic-mushrooms-to-treat-addiction-depression-anxiety-60-minutes-2020-08-16>.
12. Pollan M. *How to change your mind: what the new science of psychedelics teaches us about consciousness, dying, addiction, depression, and transcendence*. New York, NY: Penguin Press; 2018.
13. Schultes RE, et al. *Plants of the gods: their sacred, healing, and hallucinogenic powers*. Rochester, VT: Healing Arts Press; 1992.
14. Carhart-Harris RL, Goodwin GM. The therapeutic potential of psychedelic drugs: past, present, and future. *Neuropsychopharmacology* 2017;42(11):2105-13.
15. U. S. Burden of Disease Collaborators, et al. The state of US health, 1990-2016: burden of diseases, injuries, and risk factors among US states. *JAMA* 2018;319(14):1444-72.
16. Calvey T, Howells FM. An introduction to psychedelic neuroscience. *Prog Brain Res* 2018;242:1-23.
17. De Gregorio D, et al. d-Lysergic acid diethylamide, psilocybin, and other classic hallucinogens: mechanism of action and potential therapeutic applications in mood disorders. *Prog Brain Res* 2018;242:69-96.

18. de la Torre R, et al. Non-linear pharmacokinetics of MDMA ("ecstasy") in humans. *Br J Clin Pharmacol* 2000;49(2):104-9.
19. Gudelsky GA, Yamamoto BK. Actions of 3,4-methylenedioxymethamphetamine (MDMA) on cerebral dopaminergic, serotonergic and cholinergic neurons. *Pharmacol Biochem Behav* 2008;90(2):198-207.
20. Hysek CM, et al. MDMA enhances emotional empathy and prosocial behavior. *Soc Cogn Affect Neurosci* 2014;9(11):1645-52.
21. Dumont GJ, et al. Increased oxytocin concentrations and prosocial feelings in humans after ecstasy (3,4-methylenedioxymethamphetamine) administration. *Soc Neurosci* 2009;4(4):359-66.
22. Hoffmann A. *LSD, my problem child: reflections on sacred drugs, mysticism and science*. Sarasota, FL: Multidisciplinary Association for Psychedelic Studies; 1983.
23. Johnson M, et al. Human hallucinogen research: guidelines for safety. *J Psychopharmacol* 2008;22(6):603-20.
24. Johnson MW, et al. Pilot study of the 5-HT_{2A}R agonist psilocybin in the treatment of tobacco addiction. *J Psychopharmacol* 2014;28(11):983-92.
25. Bogenschutz MP, et al. Psilocybin-assisted treatment for alcohol dependence: a proof-of-concept study. *J Psychopharmacol* 2015;29(3):289-99.
26. Griffiths RR, et al. Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: a randomized double-blind trial. *J Psychopharmacol* 2016;30(12):1181-97.
27. Grob CS, et al. Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer. *Arch Gen Psychiatry* 2011;68(1):71-8.
28. Ross S, et al. Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial. *J Psychopharmacol* 2016;30(12):1165-80.
29. Anderson BT, et al. Psilocybin-assisted group therapy for demoralized older long-term AIDS survivor men: an open-label safety and feasibility pilot study. *EClinicalMedicine* 2020;27:100538.
30. Agin-Lieb GI, et al. Long-term follow-up of psilocybin-assisted psychotherapy for psychiatric and existential distress in patients with life-threatening cancer. *J Psychopharmacol* 2020;34(2):155-66.
31. Carhart-Harris RL, et al. Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. *Lancet Psychiatry* 2016;3(7):619-27.
32. Brooks M. FDA grants psilocybin second breakthrough therapy designation for resistant depression. *Medscape Psychiatry News* 2019 Nov 25. <https://www.medscape.com/viewarticle/921789>.
33. Davis AK, et al. Effects of psilocybin-assisted therapy on major depressive disorder: a randomized clinical trial. *JAMA Psychiatry* 2020 Nov 4. Online ahead of print.
34. Carbonaro TM, et al. Survey study of challenging experiences after ingesting psilocybin mushrooms: acute and enduring positive and negative consequences. *J Psychopharmacol* 2016;30(12):1268-78.
35. Rogers G, et al. The harmful health effects of recreational ecstasy: a systematic review of observational evidence. *Health Technol Assess* 2009;13(6):iii-iv, ix-xii, 1-315.
36. Mithoefer MC, et al. MDMA-assisted psychotherapy for treatment of PTSD: study design and rationale for phase 3 trials based on pooled analysis of six phase 2 randomized controlled trials. *Psychopharmacology (Berl)* 2019;236(9):2735-45.
37. Mithoefer MC, et al. Durability of improvement in post-traumatic stress disorder symptoms and absence of harmful effects or drug dependency after 3,4-methylenedioxymethamphetamine-assisted psychotherapy: a prospective long-term follow-up study. *J Psychopharmacol* 2013;27(1):28-39.
38. Mithoefer MC, et al. The safety and efficacy of (+/-)3,4-methylenedioxymethamphetamine-assisted psychotherapy in subjects with chronic, treatment-resistant posttraumatic stress disorder: the first randomized controlled pilot study. *J Psychopharmacol* 2011;25(4):439-52.
39. Beaussant Y, et al. Defining the roles and research priorities for psychedelic-assisted therapies in patients with serious illness: expert clinicians' and investigators' perspectives. *J Palliat Med* 2020;23(10):1323-34.
40. Rosa WE, et al. Fostering nurse engagement in psychedelic-assisted therapies for patients with serious illness. *J Palliat Med* 2020;23(10):1288-9.
41. Denise-Lalonde D, Estefan A. Emerging psychedelic-assisted therapies: implications for nursing practice. *Journal of Mental Health and Addiction Nursing* 2020;4(1):e1-e13.
42. Rosa WE, et al. Palliative nursing and sacred medicine: a holistic stance onentheogens, healing, and spiritual care. *J Holist Nurs* 2019;37(1):100-6.
43. Dorsen C, et al. Ceremonial "plant medicine" use and its relationship to recreational drug use: an exploratory study. *Addict Res Theory* 2019;27(2):68-75.
44. Hope S, Rosa WE. Holistic care of the spirit: the use ofentheogens in patients with advanced serious illness *Beginnings* 2018;38(4):18-21.
45. Penn AD, et al. Psychedelic-assisted psychotherapy practices and human caring science: toward a care-informed model of treatment [in press]. *J Humanist Psychol* 2021;61.



TEST INSTRUCTIONS

- Read the article. Take the test for this nursing continuing professional development (NCPD) activity online at www.nursingcenter.com/ce/ajn. Tests can no longer be mailed or faxed.
- You'll need to create an account (it's free!) and log in to your personal NCPD planner account before taking online tests. Your planner will keep track of all your Lippincott Professional Development (LPD) online NCPD activities for you.
- There's only one correct answer for each question. The passing score for this test is 7 correct answers. If you pass, you can print your certificate of earned contact hours and access the answer key. If you fail, you have the option of taking the test again at no additional cost.
- For questions, contact LPD: 1-800-787-8985.
- Registration deadline is June 2, 2023.



PROVIDER ACCREDITATION

LPD will award 2 contact hours for this NCPD activity. LPD is accredited as a provider of NCPD by the American Nurses Credentialing Center's Commission on Accreditation.

This activity is also provider approved by the California Board of Registered Nursing, Provider Number CEP 11749 for 2 contact hours. LPD is also an approved provider of continuing nursing education by the District of Columbia, Georgia, and Florida, CE Broker #50-1223. Your certificate is valid in all states.

PAYMENT

The registration fee for this test is \$21.95.